UK laboratory and office fit-out specialist Bulb joins Unispace Life Sciences
As part of our continued growth in the life sciences sector, we’ve acquired UK laboratory and office fit-out specialist, Bulb.
The move demonstrates our continued commitment to grow and deepen our life sciences expertise and offer globally and follows on from the acquisition of BioPharma Engineering, a life sciences engineering consulting firm in 2022. Bulb will begin operating as ‘Unispace Life Sciences’, part of Unispace Global, with a highly experienced team dedicated to creating inspiring facilities, labs and workplaces for this sector.
Bulb designs and builds inspiring working environments in the life sciences sector, including R&D facilities, high-tech laboratory spaces, production facilities, and corporate offices. Bulb operates across the UK and has delivered complex projects for clients including Kadans Science Partners, Advanced Research Clusters (ARC) and Astroscale.
CEO at Unispace Life Sciences, John O’Reilly said:
“We are thrilled to welcome Bulb to our growing life sciences segment. Our businesses are well aligned, we share similar values, growth ambitions, and our combined teams have a wealth of experience to offer clients.
Life sciences is one of the strongest performing sectors in the UK and to maintain business growth these firms need access to quality facilities and working environments that attract the best talent, drive innovation, and enables collaboration. With our new team on board, we are well placed to support clients with their changing needs in a fast-moving market.”
Managing Director at Bulb, Derek Jones said: “We are excited to join a fast-growing, global business such as Unispace Life Sciences; our joined-up team of experts will be able to offer clients a much wider range of capabilities and services. We look forward to beginning our new journey as Unispace Life Sciences and continuing to deliver inspiring, sustainable, work environments that address the challenges today’s life sciences businesses are facing.”
John offers our life sciences clients strategic consulting on phased investments, long-term planning, expansion and capacity increases. A trusted advisor within the pharmaceutical arena with over 30 years’ experience in the industry, he has overseen delivery of some of the world’s most complex drug manufacturing facilities and projects; new peptide suites, cell and gene therapy, site upgrades and capacity expansions, and continuous API manufacturing facilities.